Hi Team, Good morning,

I am currently conducting research using the SCMD dataset for my academic paper and have identified a potential anomaly in the data for the product Rituximab. Typically, the quantity recorded is around ~500,000, but for February 2025, it is listed as 500,000,000. This discrepancy is significantly impacting the indicative cost calculations.

Could you please assist in reviewing and correcting this data point? Addressing this issue would greatly benefit fellow researchers and other workstreams relying on this dataset.

Here is the link to the file for reference: https://opendata.nhsbsa.net/dataset/secondary-care-medicines-data-indicative-price/resource/35796fc2-15d4-43cd-9a1a-594002906b8c

Thank you for your support, Arunkumar Balaraman